{"title":"肌萎缩侧索硬化症的诊断前洞察:临床症状和药物使用","authors":"Chunyang Pang, Wen Cao, Jiali Xie, Yaojia Li, Luyi Zhu, Huan Yu, Dongsheng Fan, Binbin Deng","doi":"10.1002/jcsm.70003","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Amyotrophic lateral sclerosis (ALS) has a prolonged latency period, though its preclinical characteristics remain poorly understood. This study uses UK Biobank data to explore and compare ALS's pre-diagnostic features, including symptoms and medication use, aiming to provide insights into the disease's underlying mechanisms.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Clinical symptoms and medications were identified from self-reports, hospital records, and death registry data. Propensity score matching was used to match ALS with Alzheimer's disease (<span>AD</span>) and Parkinson's disease (PD), ensuring balance in socioeconomic factors to compare symptoms 0–5 years before diagnosis. Cox regression analysis was applied to assess the associations between medication use and the risk of incident ALS and mortality after ALS diagnosis.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 753 ALS cases were observed in 502 417 participants, with an incidence rate of 10.58 per 100 000 person-years. In the ALS cohort, the male-to-female ratio was 2.9, with a median age at onset of 64.61 years (Interquartile range (IQR): 56.80–71.31) and a median survival time post-diagnosis of 9.08 months (IQR: 3.18–18.98), while females (log-rank <i>p</i> = 0.038) and individuals with earlier (< 64.61 years) disease onset (log-rank <i>p</i> < 0.001) had longer survival periods. In the 5 years prior to diagnosis, ALS showed a higher incidence of falls compared to <span>ad</span> (11.3% vs. 3.2%, <i>p</i> < 0.001), but a lower incidence than PD (10.7% vs. 28.3%, <i>p</i> < 0.001). Additionally, ALS had a lower incidence of depression (4.6% vs. 25.6%, <i>p</i> < 0.001), anxiety (3.5% vs. 18.1%, <i>p</i> < 0.001), sleep disorders (1.4% vs. 7.2%, <i>p</i> < 0.001), hypotension (3.4% vs. 30.5%, <i>p</i> < 0.001), constipation (0.3% vs. 4.9%, <i>p</i> < 0.001), and urinary dysfunction (2.2% vs. 8.7%, <i>p</i> < 0.001) compared with PD. The use of calcium channel blockers may be a risk factor for incident ALS (adjusted HR 1.61, 95% CI: 1.22–2.12, <i>p</i> < 0.001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Pre-diagnostic presentations of falls are more frequent in ALS than in <span>AD</span>, but less frequent than in PD. However, ALS exhibits fewer psychiatric symptoms and autonomic dysfunction compared with PD. The use of calcium channel blockers may be associated with an increased risk of developing ALS in the future.</p>\n </section>\n </div>","PeriodicalId":48911,"journal":{"name":"Journal of Cachexia Sarcopenia and Muscle","volume":"16 4","pages":""},"PeriodicalIF":9.1000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.70003","citationCount":"0","resultStr":"{\"title\":\"Prediagnosis Insights Into Amyotrophic Lateral Sclerosis: Clinical Symptoms and Medication Use\",\"authors\":\"Chunyang Pang, Wen Cao, Jiali Xie, Yaojia Li, Luyi Zhu, Huan Yu, Dongsheng Fan, Binbin Deng\",\"doi\":\"10.1002/jcsm.70003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Amyotrophic lateral sclerosis (ALS) has a prolonged latency period, though its preclinical characteristics remain poorly understood. This study uses UK Biobank data to explore and compare ALS's pre-diagnostic features, including symptoms and medication use, aiming to provide insights into the disease's underlying mechanisms.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>Clinical symptoms and medications were identified from self-reports, hospital records, and death registry data. Propensity score matching was used to match ALS with Alzheimer's disease (<span>AD</span>) and Parkinson's disease (PD), ensuring balance in socioeconomic factors to compare symptoms 0–5 years before diagnosis. Cox regression analysis was applied to assess the associations between medication use and the risk of incident ALS and mortality after ALS diagnosis.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>A total of 753 ALS cases were observed in 502 417 participants, with an incidence rate of 10.58 per 100 000 person-years. In the ALS cohort, the male-to-female ratio was 2.9, with a median age at onset of 64.61 years (Interquartile range (IQR): 56.80–71.31) and a median survival time post-diagnosis of 9.08 months (IQR: 3.18–18.98), while females (log-rank <i>p</i> = 0.038) and individuals with earlier (< 64.61 years) disease onset (log-rank <i>p</i> < 0.001) had longer survival periods. In the 5 years prior to diagnosis, ALS showed a higher incidence of falls compared to <span>ad</span> (11.3% vs. 3.2%, <i>p</i> < 0.001), but a lower incidence than PD (10.7% vs. 28.3%, <i>p</i> < 0.001). Additionally, ALS had a lower incidence of depression (4.6% vs. 25.6%, <i>p</i> < 0.001), anxiety (3.5% vs. 18.1%, <i>p</i> < 0.001), sleep disorders (1.4% vs. 7.2%, <i>p</i> < 0.001), hypotension (3.4% vs. 30.5%, <i>p</i> < 0.001), constipation (0.3% vs. 4.9%, <i>p</i> < 0.001), and urinary dysfunction (2.2% vs. 8.7%, <i>p</i> < 0.001) compared with PD. The use of calcium channel blockers may be a risk factor for incident ALS (adjusted HR 1.61, 95% CI: 1.22–2.12, <i>p</i> < 0.001).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Pre-diagnostic presentations of falls are more frequent in ALS than in <span>AD</span>, but less frequent than in PD. However, ALS exhibits fewer psychiatric symptoms and autonomic dysfunction compared with PD. The use of calcium channel blockers may be associated with an increased risk of developing ALS in the future.</p>\\n </section>\\n </div>\",\"PeriodicalId\":48911,\"journal\":{\"name\":\"Journal of Cachexia Sarcopenia and Muscle\",\"volume\":\"16 4\",\"pages\":\"\"},\"PeriodicalIF\":9.1000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jcsm.70003\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Cachexia Sarcopenia and Muscle\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70003\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"GERIATRICS & GERONTOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cachexia Sarcopenia and Muscle","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jcsm.70003","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GERIATRICS & GERONTOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景肌萎缩性侧索硬化症(ALS)的潜伏期较长,但其临床前特征尚不清楚。本研究使用UK Biobank数据来探索和比较ALS的诊断前特征,包括症状和药物使用,旨在提供对疾病潜在机制的见解。方法通过自我报告、医院记录和死亡登记资料确定临床症状和用药情况。倾向评分匹配用于将ALS与阿尔茨海默病(AD)和帕金森病(PD)进行匹配,确保在诊断前0-5年比较症状时社会经济因素的平衡。应用Cox回归分析评估药物使用与ALS发病风险和ALS诊断后死亡率之间的关系。结果502 417例受试者共观察到753例ALS病例,发病率为10.58 / 10万人-年。在ALS队列中,男女比例为2.9,发病年龄中位数为64.61岁(四分位间距(IQR): 56.80-71.31),诊断后生存时间中位数为9.08个月(IQR: 3.18-18.98),而女性(log-rank p = 0.038)和早期(<;64.61年)发病(log-rank p < 0.001)患者的生存期更长。在诊断前5年,ALS的跌倒发生率高于ad(11.3%比3.2%,p < 0.001),但低于PD(10.7%比28.3%,p < 0.001)。此外,与PD相比,ALS的抑郁(4.6% vs. 25.6%, p < 0.001)、焦虑(3.5% vs. 18.1%, p < 0.001)、睡眠障碍(1.4% vs. 7.2%, p < 0.001)、低血压(3.4% vs. 30.5%, p < 0.001)、便秘(0.3% vs. 4.9%, p < 0.001)和泌尿功能障碍(2.2% vs. 8.7%, p < 0.001)的发生率较低。钙通道阻滞剂的使用可能是ALS发生的一个危险因素(调整后风险比1.61,95% CI: 1.22-2.12, p < 0.001)。结论ALS患者的跌倒诊断前表现高于AD患者,但低于PD患者。然而,与PD相比,ALS表现出较少的精神症状和自主神经功能障碍。钙通道阻滞剂的使用可能与将来发生ALS的风险增加有关。
Prediagnosis Insights Into Amyotrophic Lateral Sclerosis: Clinical Symptoms and Medication Use
Background
Amyotrophic lateral sclerosis (ALS) has a prolonged latency period, though its preclinical characteristics remain poorly understood. This study uses UK Biobank data to explore and compare ALS's pre-diagnostic features, including symptoms and medication use, aiming to provide insights into the disease's underlying mechanisms.
Methods
Clinical symptoms and medications were identified from self-reports, hospital records, and death registry data. Propensity score matching was used to match ALS with Alzheimer's disease (AD) and Parkinson's disease (PD), ensuring balance in socioeconomic factors to compare symptoms 0–5 years before diagnosis. Cox regression analysis was applied to assess the associations between medication use and the risk of incident ALS and mortality after ALS diagnosis.
Results
A total of 753 ALS cases were observed in 502 417 participants, with an incidence rate of 10.58 per 100 000 person-years. In the ALS cohort, the male-to-female ratio was 2.9, with a median age at onset of 64.61 years (Interquartile range (IQR): 56.80–71.31) and a median survival time post-diagnosis of 9.08 months (IQR: 3.18–18.98), while females (log-rank p = 0.038) and individuals with earlier (< 64.61 years) disease onset (log-rank p < 0.001) had longer survival periods. In the 5 years prior to diagnosis, ALS showed a higher incidence of falls compared to ad (11.3% vs. 3.2%, p < 0.001), but a lower incidence than PD (10.7% vs. 28.3%, p < 0.001). Additionally, ALS had a lower incidence of depression (4.6% vs. 25.6%, p < 0.001), anxiety (3.5% vs. 18.1%, p < 0.001), sleep disorders (1.4% vs. 7.2%, p < 0.001), hypotension (3.4% vs. 30.5%, p < 0.001), constipation (0.3% vs. 4.9%, p < 0.001), and urinary dysfunction (2.2% vs. 8.7%, p < 0.001) compared with PD. The use of calcium channel blockers may be a risk factor for incident ALS (adjusted HR 1.61, 95% CI: 1.22–2.12, p < 0.001).
Conclusions
Pre-diagnostic presentations of falls are more frequent in ALS than in AD, but less frequent than in PD. However, ALS exhibits fewer psychiatric symptoms and autonomic dysfunction compared with PD. The use of calcium channel blockers may be associated with an increased risk of developing ALS in the future.
期刊介绍:
The Journal of Cachexia, Sarcopenia and Muscle is a peer-reviewed international journal dedicated to publishing materials related to cachexia and sarcopenia, as well as body composition and its physiological and pathophysiological changes across the lifespan and in response to various illnesses from all fields of life sciences. The journal aims to provide a reliable resource for professionals interested in related research or involved in the clinical care of affected patients, such as those suffering from AIDS, cancer, chronic heart failure, chronic lung disease, liver cirrhosis, chronic kidney failure, rheumatoid arthritis, or sepsis.